Aripiprazole Tablet
Product Images NDC 70518-3090

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-3090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier plot comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis represents the proportion of subjects with relapse. The plot includes numbers of subjects at risk at multiple time points for both groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line chart depicting the proportion of subjects with relapse over a 364-day period from randomization, comparing Aripiprazole and placebo groups. The chart includes a legend identifying Aripiprazole with a solid line and placebo with a dashed line. The x-axis shows days from randomization and the y-axis shows the proportion with relapse. Below the x-axis, the number of subjects at risk in each group is listed at various time points.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing the fold change and 90% confidence interval of Dehydro-Aripiprazole exposure metrics (AUC and Cmax) relative to reference without interacting drugs. The chart compares the effects of CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam on Aripiprazole metabolism.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot illustrating pharmacokinetic (PK) interactions showing fold change and 90% confidence intervals for various drugs relative to a reference without interacting drug. The x-axis represents change relative to reference (0.5 to 3.0), and the y-axis lists drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (with O-desmethylvenlafaxine), and escitalopram. Different PK parameters such as DM/DR, AUC, Cmax, and INR are indicated.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled "Aripiprazole Fold Change and 90% CI" comparing the change relative to reference for AUC and Cmax parameters under various conditions including CYP2D6 metabolizer status, gender, age categories, hepatic impairment levels, and severe renal impairment. Confidence intervals are shown for each comparison.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displaying pharmacokinetic changes (AUC and Cmax) relative to reference under different conditions including CYP2D6 metabolism, gender, age, hepatic impairment, and severe renal impairment. Each condition is shown with corresponding effect size points and 90% confidence intervals on a horizontal axis representing change relative to reference.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart showing the fold change and 90% confidence intervals for Aripiprazole exposure (AUC and Cmax) when administered with various interacting drugs including CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam. The horizontal axis shows change relative to a reference without interacting drug.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 2 mg oral tablet label showing a quantity of 30 tablets. The label includes the NDC number 70518-3090-00 and repackaging information by RemedyRepack Inc., Indiana, PA. Manufacturer is Ascend Labs, LLC, Montvale, NJ. The label states storage instructions and directs users to the package insert for directions for use.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of the active ingredient Aripiprazole, showing its molecular arrangement with chlorine atoms, nitrogen, and oxygen.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole (solid blue line) and placebo (dashed red line). The graph includes the number of subjects at risk at various time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.